AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27837009 — intervention group
Group type: EXPERIMENTAL
Intervention: SafeCare Implementation with Technology‐Assistance (SC‐TA)
Number of subjects: 31
Study 27837009 — intervention group
Group type: COMPARATOR
Intervention: SafeCare Implementation as Usual (SC‐IU)
Number of subjects: 31
Study 25741781 — intervention group
Group type: EXPERIMENTAL
Intervention: upper‐evaluated feedback
Number of subjects: 61
Study 25741781 — intervention group
Group type: EXPERIMENTAL
Intervention: accurate feedback
Number of subjects: 61
Study 25741781 — intervention group
Group type: EXPERIMENTAL
Intervention: lower‐evaluated feedback
Number of subjects: 61
Study 25741781 — intervention group
Group type: COMPARATOR
Intervention: no feedback
Number of subjects: 61
Study 24022796 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians declining patient enrollment
Number of subjects: 3764
Study 24022796 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for physician refusals
Number of subjects: 3764
Study 24022796 — intervention group
Group type: COMPARATOR
Intervention: Experience of research personnel
Number of subjects: 3764
Study 24022796 — intervention group
Group type: COMPARATOR
Intervention: Unit type
Number of subjects: 3764
Study 24022796 — intervention group
Group type: COMPARATOR
Intervention: Enrollment years
Number of subjects: 3764
Study 22091267 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal beclomethasone spray
Number of subjects: 92
Study 22091267 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin and decongestant (control group)
Number of subjects: 92
Study 19782925 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily walking distance measured by pedometer over one week
Number of subjects: 0
Study 17095328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine
Number of subjects: 319
Study 17095328 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine
Number of subjects: 319
Study 14687321 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive review and recommended modification of a patient's medication regimen
Number of subjects: 133
Study 14687321 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 133
Study 11576399 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly breathable (HB) diapers
Number of subjects: 0
Study 11576399 — intervention group
Group type: COMPARATOR
Intervention: Standard, nonbreathable disposable diapers
Number of subjects: 0
Study 11576399 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathable diaper-covered sites
Number of subjects: 0
Study 11576399 — intervention group
Group type: COMPARATOR
Intervention: Control sites (standard diaper)
Number of subjects: 0
Study 9401879 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Performance Test (CPT)
Number of subjects: 112
Study 9401879 — intervention group
Group type: EXPERIMENTAL
Intervention: Conners Parent‐Teacher Rating Scale
Number of subjects: 112
Study 7965276 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibition with quinapril
Number of subjects: 40
Study 7965276 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (diuretic, beta-blocker or both)
Number of subjects: 40
Study 3632394 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment
Number of subjects: 54
Study 3632394 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 31856942 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help intervention (low-intensity psychological intervention based on behavioral activation adapted for autism)
Number of subjects: 70
Study 31856942 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (standard NHS care for depression)
Number of subjects: 70
Study 31856942 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help intervention
Number of subjects: 70
Study 29307330 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin-type fructan prebiotic (Orafti® Synergy 1; 16 g/d)
Number of subjects: 34
Study 29307330 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Glucidex® 29 Premium; 16 g/d)
Number of subjects: 34
Study 26409473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 19
Study 26409473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 24507631 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypervigilant condition
Number of subjects: 71
Study 24507631 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 71
Study 21874605 — intervention group
Group type: EXPERIMENTAL
Intervention: Group mantram intervention
Number of subjects: 66
Study 20602694 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy adherence
Number of subjects: 386
Study 17262184 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy without fusion (ACD)
Number of subjects: 551
Study 15677490 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA Step 2 diet plus endurance exercise
Number of subjects: 62
Study 11792139 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (glycoprotein IIb/IIIa inhibitor)
Number of subjects: 9461
Study 11792139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9461
Study 11792139 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 9461
Study 10579750 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II antagonists at initial doses
Number of subjects: 11281
Study 10579750 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II antagonists at doubled doses
Number of subjects: 11281
Study 10579750 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg daily added to initial doses of angiotensin II antagonists
Number of subjects: 11281
Study 8571305 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (t‐PA) antigen
Number of subjects: 1592
Study 8571305 — intervention group
Group type: EXPERIMENTAL
Intervention: fibrin D‐dimer
Number of subjects: 1592
Study 8571305 — intervention group
Group type: EXPERIMENTAL
Intervention: von Willebrand factor (vWF)
Number of subjects: 1592
Study 2346518 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting ibuprofen (2,400 mg/day)
Number of subjects: 18
Study 2346518 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (200 mg/day)
Number of subjects: 18
Study 2346518 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study 465410 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1%
Number of subjects: 0
Study 465410 — intervention group
Group type: COMPARATOR
Intervention: Atropine 1%
Number of subjects: 0
Study 30794229 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised home exercise using a web-based platform (web PT)
Number of subjects: 290
Study 30794229 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised home exercise using a printed paper manual (paper PT)
Number of subjects: 290
Study 30794229 — intervention group
Group type: COMPARATOR
Intervention: Outpatient physical therapy (outpatient PT)
Number of subjects: 290
Study 30794229 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised home exercise (both web PT and paper PT)
Number of subjects: 290
Study 30794229 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee Injury and Osteoarthritis Outcome Score (KOOS)
Number of subjects: 290
Study 30794229 — intervention group
Group type: EXPERIMENTAL
Intervention: Time back to activities of daily living, time off narcotics
Number of subjects: 290
Study 28874304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure with ProSeal
Number of subjects: 31
Study 28874304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure with Classic
Number of subjects: 31
Study 28874304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure with LT
Number of subjects: 31
Study 28874304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure with Supreme
Number of subjects: 31
Study 28874304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure with air-Q
Number of subjects: 31
Study 28874304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure with i-gel
Number of subjects: 31
Study 28874304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure with all SGDs
Number of subjects: 31
Study 28874304 — intervention group
Group type: COMPARATOR
Intervention: Sham pressure with ProSeal
Number of subjects: 31
Study 28874304 — intervention group
Group type: COMPARATOR
Intervention: Sham pressure with Classic
Number of subjects: 31
Study 28874304 — intervention group
Group type: COMPARATOR
Intervention: Sham pressure with LT
Number of subjects: 31
Study 28874304 — intervention group
Group type: COMPARATOR
Intervention: Sham pressure with Supreme
Number of subjects: 31
Study 28874304 — intervention group
Group type: COMPARATOR
Intervention: Sham pressure with air-Q
Number of subjects: 31
Study 28874304 — intervention group
Group type: COMPARATOR
Intervention: Sham pressure with i-gel
Number of subjects: 31
Study 25630627 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin dentifrice (2% atorvastatin)
Number of subjects: 36
Study 25630627 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 36
Study 23982340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus QD 0.2 mg/kg per day (Arm 2)
Number of subjects: 976
Study 23982340 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus BD 0.2 mg/kg per day (Arm 1)
Number of subjects: 976
Study 23982340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus QD 0.3 mg/kg per day (Arm 3)
Number of subjects: 976
Study 23982340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus QD 0.2 mg/kg per day with mycophenolate mofetil, basiliximab, and corticosteroids (Arm 4)
Number of subjects: 976
Study 20110160 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Lifestyle Intervention Program (CLIP)
Number of subjects: 65
Study 20110160 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus qualitative lifestyle (S+L)
Number of subjects: 65
Study 20110160 — intervention group
Group type: COMPARATOR
Intervention: Qualitative lifestyle advice (L)
Number of subjects: 65
Study 19234513 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention (exercise, relaxation, psychoeducation)
Number of subjects: 42
Study 19234513 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 42
Study 17935515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 200
Study 17935515 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (control)
Number of subjects: 200
Study 17935515 — intervention group
Group type: COMPARATOR
Intervention: Pimecrolimus cream 1% and Vehicle cream (control)
Number of subjects: 200
Study 15065957 — intervention group
Group type: EXPERIMENTAL
Intervention: Role induction session at intake
Number of subjects: 267
Study 15065957 — intervention group
Group type: COMPARATOR
Intervention: Standard group orientation
Number of subjects: 267
Study 11468422 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of SQV SGC twice daily + 100 mg of RTV twice daily (normal breakfast)
Number of subjects: 6
Study 11468422 — intervention group
Group type: COMPARATOR
Intervention: 400 mg of SQV HGC twice daily + 400 mg of RTV twice daily (normal breakfast)
Number of subjects: 6
Study 9725473 — intervention group
Group type: EXPERIMENTAL
Intervention: Parametric method
Number of subjects: 0
Study 9725473 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-parametric method
Number of subjects: 0
Study 9725473 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust method with asymptotic distribution of the M-estimator
Number of subjects: 0
Study 9725473 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust method with bootstrap distribution
Number of subjects: 0
Study 8045143 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 20
Study 8045143 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 20
Study 2662837 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol syrup (0.25 mg/kg daily dosage)
Number of subjects: 17
Study 2662837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2662837 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol syrup
Number of subjects: 17
Study 30861635 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented reconstruction (CR)
Number of subjects: 44
Study 30861635 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw-retained reconstruction (SR)
Number of subjects: 44
Study 30861635 — intervention group
Group type: COMPARATOR
Intervention: Control (Cemented reconstruction)
Number of subjects: 44
Study 28314624 — intervention group
Group type: EXPERIMENTAL
Intervention: SVD summed score
Number of subjects: 115
Study 28314624 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter hypoattenuation score
Number of subjects: 115
Study 28314624 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean transit time (MTT)
Number of subjects: 115
Study 28314624 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to maximum flow
Number of subjects: 115
Study 25428513 — intervention group
Group type: EXPERIMENTAL
Intervention: Road running training program
Number of subjects: 10
Study 25428513 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 10
Study 23184737 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Fluticasone Furoate (FF) 2000 μg via DISKHALER(®)
Number of subjects: 24
Study 23184737 — intervention group
Group type: COMPARATOR
Intervention: Inhaled Fluticasone Propionate (FP) 1000 μg via DISKHALER(®)
Number of subjects: 24
Study 21564124 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative observation by experimenters during the 3-back task
Number of subjects: 32
Study 21564124 — intervention group
Group type: COMPARATOR
Intervention: No evaluative observation during the 3-back task
Number of subjects: 32
Study 21564124 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative observation during the 3-back task
Number of subjects: 32
Study 21564124 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative observation during the 2-back and 1-back tasks
Number of subjects: 32
Study 21564124 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative observation
Number of subjects: 32
Study 18474077 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) at a maximum dosage of 1500 mg daily
Number of subjects: 8
Study 18474077 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 8
Study 18474077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16814643 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-116800
Number of subjects: 253
Study 16814643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 12634020 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive (financial incentive pay‐out for reaching preset clinical performance targets)
Number of subjects: 40
Study 12634020 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry (financial incentives combined with access to a centralized patient registry and intervention system)
Number of subjects: 40
Study 12634020 — intervention group
Group type: COMPARATOR
Intervention: Control (distribution of printed versions of smoking cessation guidelines)
Number of subjects: 40
Study 10720048 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide, testolactone, reduced hydrocortisone dose (average of 8.7 +/- 0.6 mg/m2 x day), and fludrocortisone
Number of subjects: 28
Study 10720048 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone and fludrocortisone
Number of subjects: 28
Study 8874561 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM)
Number of subjects: 14
Study 8874561 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine (EB)
Number of subjects: 14
Study 1599348 — intervention group
Group type: EXPERIMENTAL
Intervention: Full program
Number of subjects: 5686
Study 1599348 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire only
Number of subjects: 5686
Study 6141423 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 129
Study 6141423 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 129
Study 30909110 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-force mobilization group
Number of subjects: 60
Study 30909110 — intervention group
Group type: EXPERIMENTAL
Intervention: High-force mobilization group
Number of subjects: 60
Study 30909110 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-force mobilization group
Number of subjects: 60
Study 29124494 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-session telephone-based peer coaching intervention
Number of subjects: 100
Study 27068880 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored intervention for physical activity and fruit and vegetable consumption, 8 weeks duration
Number of subjects: 790
Study 25283552 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential Aged Care Integration Program (RACIP) with gerontology nurse specialists (GNSs)
Number of subjects: 2553
Study 25283552 — intervention group
Group type: COMPARATOR
Intervention: Usual care (comparison group)
Number of subjects: 2553
Study 22445512 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant (20 mg/d) for 12 weeks
Number of subjects: 14
Study 22445512 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypocaloric dietary intervention) for 12 weeks
Number of subjects: 14
Study 20159906 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day for 8 weeks
Number of subjects: 36
Study 20159906 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 36
Study 18025538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR)
Number of subjects: 82
Study 18025538 — intervention group
Group type: COMPARATOR
Intervention: Routine cardiac catheterization
Number of subjects: 82
Study 15632467 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (bolus intravenous injection)
Number of subjects: 0
Study 11979209 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine reduction education
Number of subjects: 95
Study 10824073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron combined with dexamethasone
Number of subjects: 705
Study 10824073 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone alone
Number of subjects: 705
Study 10824073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705
Study 10824073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron and dexamethasone in high-risk group
Number of subjects: 705
Study 10824073 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone alone in high-risk group
Number of subjects: 705
Study 9064947 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h NTG-infusion (group A; 0-24 h saline infusion followed by a 24 h NTG-infusion; n = 16)
Number of subjects: 32
Study 9064947 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 h NTG-infusion (group B; 0-48 h of NTG-infusion; n = 16)
Number of subjects: 32
Study 9064947 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control for group A)
Number of subjects: 32
Study 9064947 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG-infusion (both groups)
Number of subjects: 32
Study 1433584 — intervention group
Group type: EXPERIMENTAL
Intervention: Random medical treatment
Number of subjects: 401
Study 1433584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sideline medical treatment
Number of subjects: 401
Study 1433584 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral reflux
Number of subjects: 401
Study 1433584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral reflux
Number of subjects: 401
Study 1433584 — intervention group
Group type: EXPERIMENTAL
Intervention: First-time detected reflux
Number of subjects: 401
Study 1433584 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflux detected more than 1 year before entry
Number of subjects: 401
Study 6398121 — intervention group
Group type: EXPERIMENTAL
Intervention: R 14 regimen (cyclophosphamide 2 mg/kg/iv, vincristine 0.01 mg/kg/iv, vinblastine 0.1 mg/kg/iv, 5‐fluorouracil 5 mg/kg/iv, methotrexate 0.7 mg/kg/iv, adriamycin 0.5 mg/kg/iv every 21 days)
Number of subjects: 46
Study 6398121 — intervention group
Group type: COMPARATOR
Intervention: CMF regimen (cyclophosphamide 100 mg/m2/po, methotrexate 40 mg/m2/iv, 5‐fluorouracil 600 mg/m2/iv)
Number of subjects: 46
Study 30853809 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual computer magnanimous therapy (ic‐mt)
Number of subjects: 145
Study 30853809 — intervention group
Group type: EXPERIMENTAL
Intervention: Group computer magnanimous therapy (gc‐mt)
Number of subjects: 145
Study 30853809 — intervention group
Group type: COMPARATOR
Intervention: Control group (ctrl)
Number of subjects: 145
Study 29222641 — intervention group
Group type: COMPARATOR
Intervention: Ligasure™ 5 mm (LS)
Number of subjects: 74
Study 29222641 — intervention group
Group type: EXPERIMENTAL
Intervention: Marseal™ IQ 5 mm (MS)
Number of subjects: 74
Study 27362402 — intervention group
Group type: EXPERIMENTAL
Intervention: Imported histamine 1 mg/mL
Number of subjects: 75
Study 27362402 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally-prepared histamine 1 mg/mL
Number of subjects: 75
Study 27362402 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally-prepared histamine 5 mg/mL
Number of subjects: 75
Study 27362402 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally-prepared histamine 10 mg/mL
Number of subjects: 75
Study 24823906 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Climate Schools: Alcohol and Cannabis course (n=397, five schools)
Number of subjects: 764
Study 24823906 — intervention group
Group type: COMPARATOR
Intervention: Usual health classes (n=367, five schools)
Number of subjects: 764
Study 22410608 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotated fixation method
Number of subjects: 80
Study 22410608 — intervention group
Group type: COMPARATOR
Intervention: Conventional fixation method
Number of subjects: 80
Study 20413969 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive-oil-enriched skim milk
Number of subjects: 36
Study 18343177 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine capsules
Number of subjects: 1